92125-38-7Relevant academic research and scientific papers
WITHAPERUVIN E AND NICANDRIN B, WITHANOLIDES FROM PHYSALIS PERUVIANA AND NICANDRA PHYSALOIDES
Bagghi, Anjana,Neogi, Partha,Sahai, Mahendra,Ray, Anil B.,Oshima, Yoshiteru,Hikino, Hiroshi
, p. 853 - 856 (1984)
Novel withanolides, withaperuvin E and nicandrin B, isolated from Physalis peruviana and Nicandra physaloides, were fully characterized by chemical and spectroscopic means.Key Word Index - Physalis peruviana; Nicandra physaloides; Solanaceae; withanolides; withaperuvin E; nicandrin B.
17β-Hydroxywithanolides as Sensitizers of Renal Carcinoma Cells to Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) Mediated Apoptosis: Structure-Activity Relationships
Xu, Ya-Ming,Brooks, Alan D.,Wijeratne, E. M. Kithsiri,Henrich, Curtis J.,Tewary, Poonam,Sayers, Thomas J.,Gunatilaka, A. A. Leslie
, p. 3039 - 3051 (2017/04/21)
Renal cell carcinoma (RCC) is a cancer with poor prognosis, and the 5-year survival rate of patients with metastatic RCC is 5-10%. Consequently, treatment of metastatic RCC represents an unmet clinical need. Screening of a 50 000-member library of natural and synthetic compounds for sensitizers of RCC cells to TRAIL-mediated apoptosis led to identification of the 17β-hydroxywithanolide (17-BHW), withanolide E (1), as a promising lead. To explore structure-activity relationships, we obtained natural and semisynthetic withanolides 1, 2a, 2c, and 3-36 and compared their ability to sensitize TRAIL-mediated apoptosis in a panel of renal carcinoma cells. Our findings revealed that 17-BHWs with a α-oriented side chain are superior to known TRAIL-sensitizing withanolides belonging to withaferin A class with a β-oriented side chain and demonstrated that the 17-BHW scaffold can be modified to enhance sensitization of RCCs to TRAIL-mediated apoptosis, thereby assisting development of natural-product-inspired drugs to treat metastatic RCC.
METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF APOPTOSIS INDUCING LIGANDS IN CANCER TREATMENT
-
Paragraph 0190; 0191, (2017/09/05)
Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand, which method comprises contacting the cancer cells with an apoptosis inducing ligand in conjunction with an effective amount of a compound of the formula: (I), wherein R1-R14 are as described herein. Also disclosed is a method of inducing apoptosis in cancer cells in a mammal, comprising contacting the cancer cells with the compound described herein and also contacting the cancer cells with an apoptosis inducing ligand, whereby apoptosis is induced in the cancer cells.
